Literature DB >> 11479205

p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition.

P Vahteristo1, A Tamminen, P Karvinen, H Eerola, C Eklund, L A Aaltonen, C Blomqvist, K Aittomäki, H Nevanlinna.   

Abstract

Germ-line mutations in the p53 gene predispose individuals to Li-Fraumeni syndrome (LFS). The cell cycle checkpoint kinases CHK1 and CHK2 act upstream of p53 in DNA damage responses, and recently rare germ-line mutations in CHK2 were reported in LFS families. We have analyzed CHK1, CHK2, and p53 genes for mutations in 44 Finnish families with LFS, Li-Fraumeni-like syndrome, or families phenotypically suggestive of LFS with conformation-sensitive gel electrophoresis. Five different disease-causing mutations were observed in 7 families (7 of 44 families; 15.9%): 4 in the p53 gene (5 of 44 families; 11.4%) and 1 in the CHK2 gene (2 of 44 families; 4.5%). Interestingly, the other CHK2-mutation carrier also has a mutation in the MSH6 gene. The cancer phenotype in the CHK2-families was not characteristic of LFS, and may indicate variable phenotypic expression in the rare families with CHK2 mutations. No mutations in the CHK1 gene were identified. Additional work is necessary to completely unravel the molecular background of LFS.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11479205

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  51 in total

1.  A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer.

Authors:  Pia Vahteristo; Jirina Bartkova; Hannaleena Eerola; Kirsi Syrjäkoski; Salla Ojala; Outi Kilpivaara; Anitta Tamminen; Juha Kononen; Kristiina Aittomäki; Päivi Heikkilä; Kaija Holli; Carl Blomqvist; Jiri Bartek; Olli-P Kallioniemi; Heli Nevanlinna
Journal:  Am J Hum Genet       Date:  2002-07-28       Impact factor: 11.025

2.  Chk2 is dispensable for p53-mediated G1 arrest but is required for a latent p53-mediated apoptotic response.

Authors:  Melissa T Jack; Richard A Woo; Atsushi Hirao; Alison Cheung; Tak W Mak; Patrick W K Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-03       Impact factor: 11.205

3.  CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies.

Authors: 
Journal:  Am J Hum Genet       Date:  2004-04-30       Impact factor: 11.025

4.  CHEK2 mutations in primary glioblastomas.

Authors:  Satu-Leena Sallinen; Tarja Ikonen; Hannu Haapasalo; Johanna Schleutker
Journal:  J Neurooncol       Date:  2005-08       Impact factor: 4.130

5.  Mutations in CHEK2 associated with prostate cancer risk.

Authors:  Xiangyang Dong; Liang Wang; Ken Taniguchi; Xianshu Wang; Julie M Cunningham; Shannon K McDonnell; Chiping Qian; Angela F Marks; Susan L Slager; Brett J Peterson; David I Smith; John C Cheville; Michael L Blute; Steve J Jacobsen; Daniel J Schaid; Donald J Tindall; Stephen N Thibodeau; Wanguo Liu
Journal:  Am J Hum Genet       Date:  2003-01-17       Impact factor: 11.025

6.  p53: a molecular marker for the detection of cancer.

Authors:  Mark T Boyd; Nikolina Vlatkovic
Journal:  Expert Opin Med Diagn       Date:  2008-09

7.  Alterations of Chk1 and Chk2 expression in colon cancer.

Authors:  Magdalena Stawinska; Adam Cygankiewicz; Radzislaw Trzcinski; Michal Mik; Adam Dziki; Wanda M Krajewska
Journal:  Int J Colorectal Dis       Date:  2008-08-05       Impact factor: 2.571

8.  Identification and characterization of novel SNPs in CHEK2 in Ashkenazi Jewish men with prostate cancer.

Authors:  Marc D Tischkowitz; Ahmet Yilmaz; Long Q Chen; Danielle M Karyadi; David Novak; Tomas Kirchhoff; Nancy Hamel; Sean V Tavtigian; Suzanne Kolb; Tarek A Bismar; Raquel Aloyz; Peter S Nelson; Lee Hood; Steven A Narod; Kirsten A White; Elaine A Ostrander; William B Isaacs; Kenneth Offit; Kathleen A Cooney; Janet L Stanford; William D Foulkes
Journal:  Cancer Lett       Date:  2008-06-20       Impact factor: 8.679

9.  The contribution of CHEK2 to the TP53-negative Li-Fraumeni phenotype.

Authors:  Marielle W G Ruijs; Annegien Broeks; Fred H Menko; Margreet G E M Ausems; Anja Wagner; Rogier Oldenburg; Hanne Meijers-Heijboer; Laura J van't Veer; Senno Verhoef
Journal:  Hered Cancer Clin Pract       Date:  2009-02-17       Impact factor: 2.857

10.  Selected aspects of inherited susceptibility to prostate cancer and tumours of different site of origin.

Authors:  Cezary Cybulski
Journal:  Hered Cancer Clin Pract       Date:  2007-09-15       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.